Showing results (441-450 of 523) with videos related to
Sort By:
Pageof 53
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with KRAS p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.BMC Medical Genomics|December 5, 2013
Integrated molecular portrait of non-small cell lung cancersVladimir Lazar, Chen Suo, Cedric Orear, et al.The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2025
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC RegistryThomas Hueso, Justin Cagnat, Kaïssa Ouali, et al.Cells|June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved TestDamien Vasseur, Hela Sassi, Arnaud Bayle, et al.Diagnostic and Interventional Imaging|June 8, 2025
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancerGhina Jardali, Littisha Lawrance, Lama Dawi, et al.Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.Pageof 53